This chapter investigates the multifaceted effects of weight-loss drugs beyond mere weight reduction, focusing on their potential benefits for chronic conditions such as dementia. It examines ongoing research into how these medications may influence inflammation, addiction behaviors, and safety concerns, while also addressing their efficacy across various demographics.
They were developed as diabetes drugs, then their potential for promoting significant weight loss became apparent. And now study after study seems to suggest that drugs such as Ozempic and Wegovy could have all sorts of health benefits, leading some scientists to hail them a breakthrough that could transform many chronic diseases of ageing. But what’s the mechanism for these effects and is it caused by more than weight loss? The Guardian’s science correspondent Nicola Davis tells Madeleine Finlay what is known so far. Help support our independent journalism at
theguardian.com/sciencepod